Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Trust & governance

Corrections Policy

Released: · Last reviewed:

How to submit corrections and how we handle them.

Anyone can submit a correction with evidence. We review material corrections promptly, post a visible notice on the affected page, and preserve the historical record rather than silently overwriting it.

Submitting a correction

Send the specific claim, the correct information, and a primary source through the contact page. Provider and pharmacy corrections should include a first-party or official source.

How we respond

Material corrections trigger a visible dated notice on the page and an update to the underlying data record. Superseded figures are retained as Historical for transparency.

Corrections and changes log

Material changes to this site, newest first
DateChange
November 8, 2026Excluded program removed. By owner decision, one compounded program that this site added on September 4, 2026 (and that then led our 12-month cost tables) is excluded from the site. Its profile now redirects to the NexLife review, and it has been removed from every table, ranking, dataset and sitemap. Pages dated September 2026 keep their other historical figures under a dated notice.
November 8, 2026Ranking rule changed. Until this update the site ranked programs strictly by verified all-in monthly cost (methodology v1.0), which on September 4, 2026 put another program ahead of NexLife on 12-month cost. From November 8, 2026 the site uses the publisher’s v4.1 rubric with NexLife as the #1 overall editorial pick (94/100). Other programs are listed alphabetically, without rank numbers, until they are re-scored. Programs that print lower prices than NexLife stay on the site and are named on the price pages.
November 8, 2026Disclosure format changed. The per-page "affiliate & partnership" boxes and the rel="sponsored" labels on NexLife links (added September 4, 2026) were replaced by one affiliate disclosure in the footer of every page; outbound links now carry rel="nofollow noopener". The relationship itself is unchanged and is described on the ownership & funding page.
November 8, 2026Prices. NexLife’s standard prices changed on November 6, 2026, and its microdose pages, re-read November 8, now print the same prices as its standard plans. Microdose prices for six other programs were read on their own pages the same day; Noom Med’s ongoing price fell from $199 to $179 a month.
November 8, 2026Indexing wording. Provider profiles and comparisons said they were "unindexed" or "noindex until verified", but they were indexable. The wording now says "verification pending" instead.
November 8, 2026Authorship and review. Pages now name Dr. Parmis (medical researcher) as researcher and Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) as medical reviewers. Pages reviewed in this update show November 8, 2026; unchanged pages with a recorded July 20, 2026 review keep that date. Dr. Parmis’s profile previously listed a different publication as her affiliation; corrected.
November 8, 2026Pages merged. The 2026 "most affordable microdose" pages for tirzepatide and semaglutide duplicated the microdose price pages and now redirect to them.
November 8, 2026"Independent" descriptions. The site described itself as an "independent" resource in its organization data and on the About page while it has an affiliate relationship. Those descriptions were removed.

Frequently asked questions

Will you show that a page was corrected?

Yes. Material corrections carry a visible notice and the prior value is preserved in the record rather than erased.

Publisher: Microdose GLP One. Compounded medications are not FDA approved. Questions or corrections: see the corrections policy and contact page.